Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDAThe Motley Fool • 11/03/23
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 11/02/23
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis ConferenceBusiness Wire • 11/02/23
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up studyReuters • 10/31/23
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/30/23
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain PatientThe Motley Fool • 10/30/23
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a DecadeThe Motley Fool • 10/28/23
Vertex Pharmaceuticals (VRTX) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 10/16/23
The Surprising $5 Billion Opportunity That Drove Vertex Pharmaceuticals Stock To A Record HighInvestors Business Daily • 10/12/23